Epidemiology: The LADAchina survey in 2006 showed that the positivity rate of people over 30 years old was 5.9%. The prevalence of LADA in China is at a high level. Relationship with other autoimmune diseases: Both LADA and classical type 1 diabetes are associated with autoimmune thyroid diseases, including Addison’s disease, celiac disease and other autoimmune diseases can be combined in autoimmune polyglandular disease syndrome (APS) are present, mostly APS type III. Adult-onset type 1 diabetes and LADA are high-risk factors for autoimmune thyroid disease. Therefore, routine screening for autoimmune thyroid disease is recommended in Chinese LADA patients. Metabolic features and chronic complications: ActionLADA data from LADAChina and Europe suggest that the proportion of combined metabolic syndrome in LADA in Chinese is more inclined to type 2 diabetes and the proportion of metabolic syndrome in LADA in Europe is more inclined to classical type 1 diabetes, the reason for the difference is not clear. European data showed no significant difference between macrovascular and microvascular complications of LADA and type 2 diabetes, while related studies in China are still in progress. Diagnosis: Taking into account the national and ethnic characteristics of China, the recommended diagnostic criteria for LADA in China are: the diagnosis of diabetes is established, gestational diabetes and other special types of diabetes are excluded, and the following three items are met: positive islet autoantibodies, age older than 18 years, and no reliance on insulin therapy for at least six months after the diagnosis of diabetes. Treatment strategy: There is no unanimous consensus on the treatment of LADA internationally. Our consensus suggests that patients with LADA should avoid sulfonylureas. patients with LADA who have good metabolic status (blood glucose, HbA1c, islet function, etc.) at the time of initiation may still be considered for standard treatment regimens with fasting hypoglycemic agents other than sulfonylureas (biguanides, etc.) until progression to the insulin-dependent stage. Patients with high titers of islet autoantibodies (LADA-1) and poor metabolic status can be treated with insulin early.